Biomarkers in systemic sclerosis

Rheumatology

Volumn 47, Issue SUPPL. 5, 2009, Pages

  Doran, J P ^a   Veale, D J ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Acute phase reactants; Biomarkers; Collagen breakdown products; Endothelin; Immunoserological markers; Raynaud's phenomenon; Scleroderma; Serum N terminal pro brain natriuretic peptide; Serum pro brain natriuretic peptide; Systemic sclerosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; CD40 LIGAND; COLLAGEN; CYTOKINE; HEMOGLOBIN; INTERCELLULAR ADHESION MOLECULE 1;

ACUTE DISEASE; CELL SURFACE; CLINICAL FEATURE; CLINICAL TRIAL; COHORT ANALYSIS; CONFERENCE PAPER; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; EARLY DIAGNOSIS; ERYTHROCYTE SEDIMENTATION RATE; HEMOGLOBIN DETERMINATION; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SENSITIVITY AND SPECIFICITY; SEROLOGY; STANDARDIZATION; SYSTEMIC SCLEROSIS;

EID: 69949164232     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken270     Document Type: Conference Paper

References (17)

1. Mayes MD, Lacey JV, Beebe-Dimmer J et al. Prevalence, incidence, survival and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003;48:2246-55.
2. Steen VD, Varga J, Furst DE et al. Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis. 2008;67:703-9.
3. Cutolo M, Pizzorni C, Tuccio M et al. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. Rheumatology 2004;43:719-26.
4. Scussel-Lonzetti L, Joyal F, Raynaud JP et al. Predicting mortality in systemic sclerosis. Analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine 2002;81:154-67.
5. Bryan C, Howard Y, Brennan P, Black C, Silman A. Survival following the onset of scleroderma: Results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol 1996;35:1112-76.
6. Ferri C, Valentini G, Cozzi F et al. Systemic sclerosis. Demographic, clinical and serologic features and survival in 1012 Italian patients. Medicine 2002;81:139-53.
7. Allanore Y, Borderie D, Meune C et al. N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Arthritis Rheum 2003;48:3503-8.
8. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003;48:516-22.
9. Denton CP, Bickerstaff MC, Shiwen X et al. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol 1995; 34:1048-54.
10. Veale DJ, Kirk G, McLaren M, Belch JJ. Clinical implications of soluble intercellular adhesion molecule-1 levels in systemic sclerosis. Br J Rheumatol 1998;37:1227-8.
11. Shiwen X, Kennedy L, Renzoni EA et al. Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts. Arthritis Rheum 2007;56:4189-94.
12. Sfikakis PP, Papamichael C, Stamatelopoulos KS et al. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum 2007;56:1985-93.
13. Komura K, Fujimoto M, Matsushita T et al. Increased serum soluble CD40 levels in patients with systemic sclerosis. J Rheumatol 2007;34:353-8.
14. Allanore Y, Borderie D, Lemaréchal H, Cherruau B, Ekindjian OG, Kahan A. Correlation of serum collagen I carboxyterminal telopeptide concentrations with cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol 2003;30:68-73.
15. Istok R, Czirják L, Lukác J, Stancíková M, Rovenský J. Increased urinary pyridinoline cross-link compounds of collagen in patients with systemic sclerosis and Raynaud's phenomenon. Rheumatology 2001;40:140-6.
16. Geirsson AJ, Wollheim FA, Akesson A. Disease severity of 100 patients with systemic sclerosis over a period of 14 years: Using a modified Medsger scale. Ann Rheum Dis 2001;60:1117-22.
17. Valentini G, Della Rossa A, Bombardieri S et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001;60:592-8.